August 4, 2020

Xcenda's Ana Stojanovska Shares Insights on Market Access and Reimbursement for Cell and Gene Therapies with pharmaphorum

Xcenda has worked with 100% of the cell and gene therapies launched in the US to date—and many of the pipeline assets currently in development. With this experience and expertise, Ana Stojanovska, Vice President of Commercial Consulting at Xcenda, shares perspectives on market access and reimbursement for cell and gene therapies in a new article in pharmaphorum. 


Preparing for an influx of cell and gene therapy approvals